Drug Profile
Research programme: atherosclerosis therapeutics - InVasc Therapeutics
Alternative Names: INV 405; INV-404Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InVasc Therapeutics
- Class
- Mechanism of Action Transcription factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA